Methods of treating a meiotic kinesin associated disease
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/02
C07H-021/04
A61K-031/70
C12Q-001/68
출원번호
US-0994920
(2009-05-28)
등록번호
US-8629118
(2014-01-14)
국제출원번호
PCT/US2009/045406
(2009-05-28)
§371/§102 date
20110407
(20110407)
국제공개번호
WO2009/155025
(2009-12-23)
발명자
/ 주소
Pellman, David
출원인 / 주소
Dana-Farber Cancer Institute, Inc.
대리인 / 주소
Brinks Gilson & Lione
인용정보
피인용 횟수 :
0인용 특허 :
18
초록▼
The invention provides methods of treating a meiotic kinase-associated disease, preferably the meiotic kinase HSET, by administering an inhibitor of the meiotic kinase. Preferably, the disease is associated with the presence of supernumerary centrosomes, such as cancer. Methods of inhibiting the gro
The invention provides methods of treating a meiotic kinase-associated disease, preferably the meiotic kinase HSET, by administering an inhibitor of the meiotic kinase. Preferably, the disease is associated with the presence of supernumerary centrosomes, such as cancer. Methods of inhibiting the growth of a tumor cell by contacting the cell with an inhibitor of a meiotic kinase, preferably HSET, are also provided. Screening methods for identifying inhibitors of the meiotic kinase HSET are also provided. Methods of selecting subjects for treatment with an inhibitor of a meiotic kinase, such as HSET, are also provided.
대표청구항▼
1. A method of treating a meiotic kinesin-associated disease or disorder, wherein at least 50% of cells of the disease or disorder comprise supernumerary centrosomes, comprising administering to a subject in need of treatment thereof an RNAi agent which inhibits a meiotic kinesin selected from a kin
1. A method of treating a meiotic kinesin-associated disease or disorder, wherein at least 50% of cells of the disease or disorder comprise supernumerary centrosomes, comprising administering to a subject in need of treatment thereof an RNAi agent which inhibits a meiotic kinesin selected from a kinesin-14 family member causing: (i) disruption of the clustering of extra centrosomes in the at least 50% of the cells comprising supernumerary centrosomes, and(ii) promotion of multipolar mitoses to selectively induce cell death of the at least 50% of the cells comprising supernumerary centrosomes such that treatment of the disease or disorder is achieved. 2. The method of claim 1, wherein the disease or disorder is an autosomal disease or disorder, a centrosomal disease or disorder, a cellular proliferative disease or disorder, or cancer. 3. The method of claim 1, wherein the meiotic kinesin is HSET. 4. The method of claim 1, wherein the RNAi agent is administered orally. 5. The method of claim 1, wherein the RNAi agent is administered parenterally. 6. A method of inhibiting growth of a tumor, cancer or other malignancy, wherein at least 50% of the cancer, tumor or malignant cells comprise supernumerary centrosomes and in which cellular proliferation is associated with a meiotic kinesin, comprising contacting the tumor, cancer or malignant cells with an RNAi agent which inhibits a meiotic kinesin selected from a kinesin-14 family member causing: (i) disruption of the clustering of extra centrosomes in the at least 50% of the cells comprising supernumerary centrosomes, and(ii) promotion of multipolar mitoses to selectively induce cell death of the at least 50% of the cells comprising supernumerary centrosomes such that growth of the tumor, cancer or malignant cells is inhibited. 7. The method of claim 6, wherein the meiotic kinesin is HSET. 8. The method of claim 6, wherein said contacting comprises direct injection of the RNAi agent into the tumor. 9. A method of inhibiting proliferation of a tumor, cancer or other malignancy, where at least 50% of the tumor, cancer or malignant cells comprise supernumerary centrosomes and in which cellular proliferation is associated with a meiotic kinesin, comprising contacting the tumor, cancer or malignant cells with an RNAi agent which inhibits a meiotic kinesin selected from a kinesin-14 family member causing: (i) disruption of the clustering of extra centrosomes in the at least 50% of the cells comprising supernumerary centrosomes, and(ii) promotion of multipolar mitoses to selectively induce cell death of the at least 50% of the cells comprising supernumerary centrosomes such that inhibition of tumor, cancer or malignant cell proliferation is achieved. 10. The method of claim 9, wherein the meiotic kinesin is HSET. 11. The method of claim 1, wherein at least 75% of cells of the disease or disorder comprise supernumerary centrosomes. 12. The method of claim 1, wherein at least 90% of cells of the disease or disorder comprise supernumerary centrosomes.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (18)
Jeffrey T. Finer ; Fady Malik ; Roman Sakowicz ; Christopher Shumate ; Kenneth Wood, Compositions and assays utilizing ADP or phosphate for detecting protein modulators.
La Zor Clair G. (13054 Rose St. Cerritos CA 90701), Instrument for locating faults in aircraft passenger reading light and attendant call control system.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Loughrey Helen C. (Vancouver CAX) Cullis Pieter R. (Vancouver CAX) Bally Marcel B. (Bowen Island CAX) Choi Lewis S. (Burnaby CAX), Method for protein-liposome coupling.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Eppstein Deborah A. (Los Altos CA) Fraser-Smith Elizabeth B. (Los Altos CA) Matthews Thomas R. (Los Gatos CA), Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.